New Posts New Posts RSS Feed - TNBC and Her2
  FAQ FAQ  Forum Search   Events   Register Register  Login Login

TNBC and Her2

 Post Reply Post Reply
Author
2020TNBC View Drop Down
Newbie
Newbie
Avatar

Joined: May 27 2020
Location: Galway ireland
Status: Offline
Points: 10
Post Options Post Options   Thanks (0) Thanks(0)   Quote 2020TNBC Quote  Post ReplyReply Direct Link To This Post Topic: TNBC and Her2
    Posted: Dec 08 2020 at 7:29am
hi my mom was diagnosed with TNBC about a year ago and went through chemo, surgery, and radiation. She had a 70% partial response to chemo and surgery went well clear margins and clear lymph nodes. She is know talking xeloda for 6 months as a precaution. Just wondering her first biopsy showed tnbc breast cancer and further testing was done after chemo and surgery and showed positive her 2 so she is talking herceptin for 1 year know. Just wondering was the cancer her 2 all along because I heard itís not possible to be both triple negative and Her 2 
Back to Top
123Donna View Drop Down
Senior Member
Senior Member
Avatar

Joined: Aug 24 2009
Location: St. Louis, MO
Status: Offline
Points: 13411
Post Options Post Options   Thanks (0) Thanks(0)   Quote 123Donna Quote  Post ReplyReply Direct Link To This Post Posted: Dec 08 2020 at 7:57am
That is a really good question.  It seems it's possible to change Her2 status after neoadjuvant therapy.

Change in HER2 status after neoadjuvant chemotherapy and the prognostic impact in patients with primary breast cancer

Abstract

Background: We aimed to assess change in HER2 status after neoadjuvant chemotherapy (NAC) in patients with primary breast cancer and the prognostic impact of such changes.

Patients and methods: The study comprised 588 patients with a non-pathologic complete response who received anthracycline and/or taxane-based regimens in NAC setting. HER2 status was assessed before NAC and in residual invasive tumor of the surgical specimens. The associations between the change in HER2 status and clinicopathological factors were assessed.

Results: Before NAC, 489 (83%) of the 588 patients had HER2-negative tumors and 99 patients (17%) had HER2-positive tumors. Eleven (2.2%) of the HER2-negative tumors changed to HER2-positive, while 33 (33%) of the HER2-positive tumors changed to HER2-negative. ER and PR-positivity before NAC were associated with loss of HER2-positivity, whereas receiving trastuzumab was not. In terms of disease-free survival, there was no difference between patients with and those without change in HER2 status after NAC in either the patients with HER2-negative tumors (P = 0.26) or with HER2-positive tumors before NAC (P = 0.23).

Conclusion: Our results showed that changes in HER2 status did not affect patients' prognosis. Further studies are needed to determine whether HER2-targeting agents can be omitted when loss of HER2-positivity is confirmed after NAC.

https://pubmed.ncbi.nlm.nih.gov/28767137/


DX IDC TNBC 6/09 age 49, Stage 1,Grade 3, 1.5cm,0/5Nodes,KI-67 48%,BRCA-,6/09bi-mx, recon, T/C X4(9/09)
11/10 Recur IM node, Gem,Carb,Iniparib 12/10,MRI NED 2/11,IMRT Radsx40,CT NED11/13,MRI NED3/15

Back to Top
 Post Reply Post Reply
  Share Topic   

Forum Jump Forum Permissions View Drop Down

Forum Software by Web Wiz Forums® version 12.01
Copyright ©2001-2018 Web Wiz Ltd.